Sanofi Aventis withdraws its marketing authorisation application for Sliwens (eplivanserin)

The European Medicines Agency has been formally notified by Sanofi Aventis of its decision to withdraw its application for a centralised marketing authorisation for the medicine Sliwens (eplivanserin), 5 mg, film-coated tablets. ... Read more